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Introduction: The prevalence of impaired cutaneous wound healing is high and treatment is difficult and often
ineffective, leading to negative social and economic impacts for our society. Innovative treatments to improve
cutaneous wound healing by promoting complete tissue regeneration are therefore urgently needed. Mesenchymal
stromal cells (MSCs) have been reported to provide paracrine signals that promote wound healing, but (i) how they
exert their effects on target cells is unclear and (ii) a suitable delivery system to supply these MSC-derived secreted
factors in a controlled and safe way is unavailable. The present study was designed to provide answers to these
questions by using the horse as a translational model. Specifically, we aimed to (i) evaluate the in vitro effects of
equine MSC-derived conditioned medium (CM), containing all factors secreted by MSCs, on equine dermal fibroblasts,
a cell type critical for successful wound healing, and (ii) explore the potential of microencapsulated equine MSCs to
deliver CM to wounded cells in vitro.
Methods: MSCs were isolated from the peripheral blood of healthy horses. Equine dermal fibroblasts from the NBL-6
(horse dermal fibroblast cell) line were wounded in vitro, and cell migration and expression levels of genes involved in
wound healing were evaluated after treatment with MSC-CM or NBL-6-CM. These assays were repeated by using the
CM collected from MSCs encapsulated in core-shell hydrogel microcapsules.
Results: Our salient findings were that equine MSC-derived CM stimulated the migration of equine dermal fibroblasts
and increased their expression level of genes that positively contribute to wound healing. In addition, we found that
equine MSCs packaged in core-shell hydrogel microcapsules had similar effects on equine dermal fibroblast migration
and gene expression, indicating that microencapsulation of MSCs does not interfere with the release of bioactive factors.
Conclusions: Our results demonstrate that the use of CM from MSCs might be a promising new therapy for impaired
cutaneous wounds and that encapsulation may be a suitable way to effectively deliver CM to wounded cells in vivo.Introduction
Cutaneous wound healing is comprised of a network of
biological processes, collectively restoring the integrity
of the skin after injury. Unfortunately, the ideal outcome
of cutaneous wound healing, which encompasses
complete tissue regeneration, is often sacrificed in favor
of quickly closing a wound with formation of fibrotic
scar tissue [1]. Fibrotic scar formation is an undesirable
result of cutaneous wound healing, not only for cosmetic
reasons but because scar tissue has compromised* Correspondence: grv23@cornell.edu
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unless otherwise stated.mechanical strength and is more sensitive to pain than
healthy skin [2]. Treating cutaneous skin wounds and re-
ducing scar tissue cause a financial burden worldwide,
and annual expenditures on products designed to
minimize scarring exceed $5 billion [3].
To understand the processes involved in cutaneous
wound healing or treat fibrotic scar tissue or both, re-
searchers commonly use laboratory rodents as models.
Although relevant information has been obtained from
studies using rodents, wound healing in these species
does not accurately mimic human tissue regeneration
[4-7]. For example, mice heal primarily by contraction
due to the presence of the panniculus carnosus in their
subcutaneous tissues, whereas humans lack this muscle
and instead rely on epithelialization to close cutaneousl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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need for an animal wound model that closely mimics
the natural processes of healing and scar formation in
humans. Horses may prove to be an ideal species in
which to study cutaneous wound healing since they also
depend on epithelial cell activity to heal skin wounds. In
addition, horses and humans both suffer from hypergra-
nulation formation, a pathological process defined as an
excess of granulation tissue beyond the amount required
to replace the tissue deficit. Hypergranulation tissue is
referred to as proud flesh in horses and keloid in
humans [8]. These common features make the horse an
attractive translational model in which to study the
underlying pathogenesis of excessive cutaneous wound
healing as well as to evaluate the potential of novel
treatments.
Mesenchymal stromal cells (MSCs) are multipotent
stromal progenitor cells with regenerative properties that
are present in a variety of tissues and organs [9]. MSCs
actively contribute to regenerative processes, as they are
involved in the inflammatory [10], proliferative [11], and
remodeling [12] phases of tissue regeneration. Although
MSCs were originally reported to contribute to tissue re-
pair by trans-differentiating into the specific cell types
needed to restore injured tissue, recent data indicate
paracrine signaling as the primary mechanism for the re-
generative effects of MSCs [13,14]. Indeed, we recently
identified angiogenic stimulating factors in the condi-
tioned medium (CM) of equine MSCs and showed that
these factors could induce proliferation and vessel for-
mation of equine endothelial cells in vitro [15]. Practic-
ally, this implies that the CM obtained from MSC
cultures, which contains all factors secreted by MSCs,
may be used as a ‘stem cell-free’ therapy in regenerative
medicine. This type of therapy offers several advantages
over cellular MSC remedies, including the absence of in-
herent toxicity, no risk for tumor formation of engrafted
cells, and no concerns about allograft-associated im-
mune rejection [16,17]. Previous reports have demon-
strated that CM obtained from human MSC cultures
can improve cutaneous wound healing, although the
underlying mechanisms remain unclear [18,19]. The po-
tential of CM obtained from equine MSC cultures to
contribute to wound healing has not been studied to
date but is essential in order to take advantage of the
horse as a physiologically relevant translational model in
which to study cutaneous wound healing.
An important aspect to take into consideration when
proposing the use of MSC-derived CM in regenerative
medicine is the development of a suitable delivery sys-
tem for these secreted products. Indeed, optimal spatial
distribution and continuous release of factors at the site
of injury are two key components of MSC treatment that
may significantly improve clinical outcome. Cellmicroencapsulation, which involves immobilization of
the cells within a polymeric semi-permeable membrane,
provides a supportive microenvironment for the cells in
which they can proliferate and release bioactive factors
while being shielded from the external environment
[20,21]. These microcapsules can be injected at the
transplantation bed, localizing the release of therapeutic
factors in a controlled way. A recent study by Xu et al.
describes the potential use of human MSCs encapsulated
in biomaterials for the treatment of cutaneous wounds,
and their initial findings were that cells ‘packaged’ in a
gelatin/poly(ethylene glycol) biomatrix mediated the
early resolution of inflammatory events and facilitated
the proliferative phases in wound healing [22]. To the
best of our knowledge, however, the use of microencap-
sulated equine MSCs in equine regenerative medicine
has not been explored to date.
Therefore, the aims of the present study were (i) to
evaluate the in vitro effects of equine MSC-derived CM
on equine dermal fibroblasts, a cell type critical for suc-
cessful wound healing, and (ii) to explore the potential
of microencapsulated equine MSCs to deliver the critical
components of CM to wounded cells in vitro. Our sali-
ent findings were that equine MSC-derived CM stimu-
lated the migration of equine dermal fibroblasts and
increased the expression levels of genes that positively
contribute to wound healing in these cells. In addition,
we found that equine MSCs packaged in core-shell
hydrogel microcapsules have similar effects on equine
dermal fibroblast migration and gene expression, sug-
gesting MSC encapsulation may be a suitable way to ef-




Equine MSCs were isolated from the peripheral blood of
three healthy warmblood mares between 8 and 12 years
old, exactly as described previously [15,23]. The blood
collection was approved by the Cornell Institutional
Animal Care and Use Committee (#2014-0038). Briefly,
blood was collected from the vena jugularis of healthy
donor horses, and peripheral blood mononuclear cells
were isolated by using density gradient centrifugation on
1.080 g/mL Percoll (GE Healthcare, Little Chalfont,
Buckinghamshire, UK) and subsequently seeded at a
density of 16 × 104 cells/cm2 in a T75 flask in culture
medium consisting of low-glucose Dulbecco’s modified
Eagle’s medium (Invitrogen, part of Thermo Fisher
Scientific, Waltham, MA, USA) supplemented with 30%
fetal bovine serum (FBS) (Atlanta Biological, Flowery
Branch, GA, USA), 10−7 M low dexamethasone (Sigma-
Aldrich, St. Louis, MO, USA), and 50 μg/mL gentamy-
cin, 1x penicillin-streptomycin, and 2 mM L-glutamine
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Cultures were maintained at 37°C with 5% CO2. At 70%
confluency, cells were removed from flasks by using
0.25% trypsin-EDTA and further cultured in expansion
medium, which is identical to the culture medium but
without dexamethasone. Equine MSCs were character-
ized by immunophenotypical protein profiling by using
flow cytometry and their potential for trilineage differen-
tiation, exactly as described previously [15]. In essence,
equine MSCs were confirmed to be positive for CD29,
CD44, CD90, and CD105 and negative for CD45,
CD79α, major histocompatibility complex II (MHC II),
and a monocyte/macrophage marker. The successful
trilineage differentiation of MSCs toward osteoblasts,
chondroblasts, and adipocytes was confirmed by using a
range of histochemical stains.
The equine dermal fibroblast cell line NBL-6 (American
Type Culture Collection, Manassas, VA, USA) was cul-
tured in standard medium consisting of minimal essential
medium (Corning) supplemented with 10% FBS (Atlanta
Biochemicals) and 1% penicillin/streptomycin (Invitrogen).
Cells were maintained at 37°C with 5% CO2.
Generation of conditioned media and pre-treatments
CM was collected from MSCs after 2 days of culture,
when cells were 70% confluent. To this end, 6 × 105
MSCs were seeded in a T75 flask in 8 mL of expansion
medium. After 48 hours, medium was collected, centri-
fuged twice for 7 minutes at 300 g to remove any cellular
debris, and used for further experiments. CM from
NBL-6 cells was used as a control and was collected
after 2 days of culture, exactly as described for MSC-
derived CM. For pre-treatment experiments, MSCs were
seeded in expansion medium supplemented with 10 ng/mL
tumor necrosis factor-alpha (TNFα) (R&D Systems,
Minneapolis, MN, USA), 20 ng/mL interferon-gamma
(IFNγ) (R&D Systems), or 150 μM cobalt chloride
(CoCl2) (Sigma-Aldrich). After 24 hours of culture, cells
were washed twice with phosphate-buffered saline
(PBS) and fed with 8 mL of fresh expansion medium.
CM was collected 24 hours later, as described above.
Microencapsulated mesenchymal stromal cells
For experiments using encapsulated MSCs, 6 × 105
MSCs were seeded per T75 flask in 8 mL of expansion
medium, and in parallel the same number of cells were
encapsulated in double-layer microparticles by using a
multi-fluidic electrostatic cell micropackaging technique
[24]. Briefly, type I collagen neutralized by 1 N sodium
hydroxide was mixed with MSCs in expansion medium
for a final concentration of 0.45 mg/mL. Cells supported
by collagen were encapsulated in 0.9% (wt/vol) alginate
hydrogel (FMC Biopolymers, Philadelphia, PA, USA) at
a concentration of about 37 cells per capsule.Microencapsulated MSCs were incubated in a crosslink-
ing bath with 100 mM calcium chloride and 5 mM bar-
ium chloride under an electrical field strength of 7 kV.
Microencapsulated MSCs were resuspended in 8 mL of
expansion medium and maintained at 37°C with 5%
CO2. Empty core-shell hydrogel microcapsules, contain-
ing no cells, were included as negative control. After
48 hours, supernatants were collected, centrifuged twice
for 7 minutes at 300 g to remove cellular debris, and
used as CM in experiments.
In vitro scratch assays
NBL-6 cells were seeded in six-well plates at a density of
6 × 104 cells/cm2. Upon 90% confluency (after approxi-
mately 24 hours), cells were washed twice with PBS and
serum-starved overnight. A linear defect was inflicted on
the monolayer by using a 200-μL pipette tip. Culture
medium was immediately removed (along with any dis-
lodged cells) and replaced with freshly collected CM, di-
luted 1:1 in expansion medium. Similar scratch assays
were repeated in the presence of 2 μg/mL mitomycin C,
which was added at the time of scratch infliction. Refer-
ence marks were made across the bottoms of the wells
with an ultrafine marker. Images of scratches were cap-
tured by using a Nikon Diaphot-TMD inverted light
microscope with an attached Cohu charge-coupled de-
vice (CCD) camera (Nikon, Melville, NY, USA), leaving
the reference marks outside the capture image field but
within the eye-piece field of view for repeatable orienta-
tion of scratches. Photographs of scratches were taken at
0, 24, and 48 hours after scratching, and migration dis-
tances of cells were calculated in a blinded-manner by
using ImageJ [25]. Widths of scratches were taken in
two places in each of three wells scratched per treat-
ment, for a total of six measurements per treatment.
Scratch width was subtracted from the time 0 scratch
widths at the same location to determine cell migration
distance. Migration distances within treatments were av-
eraged to determine overall migration.
Electric Cell-substrate Impedance Sensing
Cell migration was measured by Electric Cell-substrate
Impedance Sensing (ECIS) by using the ECIS Model Z
instrument with a 96 W array station (ECIS; Applied
BioPhysics Inc., Troy, NY, USA). Dermal fibroblasts were
seeded at a density of 2 × 105 cells per well in a 96W1E+
PET array chip (Applied BioPhysics Inc.) in standard
medium. After 24 hours, medium was removed and re-
placed with serum-free medium for at least 8 hours prior
to wounding. A uniform circular defect was created in
the cell monolayer by lethal electroporation (1,200 μA,
40 kHz) for 40 seconds by 350-μm diameter circular
electrodes located in each well of the array chip. The de-
fect created in the fibroblast monolayer will be referred
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scribed by Keese et al. [26]. Dead cells were detached
from the electrode by gently pipetting medium up and
down three times before removal. Control CM or MSC-
derived CM was added to appropriate wells, and an
alternating current (approximately 1 μA, 32 kHz) was
applied to the electrodes to measure impedance (in
ohms) and monitor wound closure in real time. As cells
migrate to repair the circular wound, they physically re-
cover the electrode, causing an increase in impedance.
The time required for re-covering the electrode was de-
termined as the number of hours it took for the imped-
ance levels in wells with the 350-μm circular wound to
return to the same values as the impedance levels in
control wells in which cells were not wounded. Cell mi-
gration was also documented by phase-contrast images
captured by using an Olympus CCX41 inverted micro-
scope equipped with an Olympus LC20 digital camera
(Olympus, Tokyo, Japan).
Gene expression analyses
NBL-6 cells were cultured in 15 × 100 mm culture dishes
until confluent. Cells were serum-starved overnight and
scratches were made. After two washes with PBS, 1:1 di-
luted CM derived from MSCs (un-stimulated, stimu-
lated, or encapsulated) or control NBL-6 was added to
each NBL-6 culture. After 24 hours, CM was removed,
monolayers were rinsed with PBS, and cells were further
cultured for another 24 hours. Subsequently, mRNA was
extracted from the cells by using an RNEasy Plus Kit in
accordance with instructions of the manufacturer (Qiagen,
Valencia, CA, USA), followed by a DNase digestion using
DNase I (Invitrogen). cDNA was synthesized by using
M-MLV Reverse Transcriptase (USB, Cleveland, OH,
USA) in accordance with the protocol of the manufac-
turer. SYBER green-based quantitative polymerase
chain reaction (qPCR) assays were carried out on an
Applied Biosystems 7500 Fast Real-Time PCR instru-
ment (Applied Biosystems, Carlsbad, CA, USA) to de-
termine fold changes of genes of interest in NBL-6 cells
incubated with CM of MSCs compared with NBL-6 in-
cubated with control CM. The comparative threshold
cycle (Ct) method (2
−ΔΔCt) was used to quantify gene
expression levels in which ΔΔCt =ΔCt(sample) – ΔCt
(reference). The previously validated reference gene
SDHA (succinate dehydrogenase complex, subunit A)
was used to normalize samples [27]. Primers to amplify
CCL2, CxCL10, IL-8, MMP1, MMP2, TMP1, plas-
minogen activator urokinase (PLAU), tissue plasmino-
gen activator (PLAT), PAI1, CTSK, annexin A2
(ANXA2), COLIII, COL1, syndecan 2 (SDC2), SDC4,
and fibronectin were designed by using Primer3 soft-
ware, based on horse sequences found in the National
Center of Biotechnology Information GenBank, andprimer sequences are listed in Table 1. All samples
were run in triplicate.
Cell viability assays
To ensure that mitomycin C was not toxic to NBL-6 fi-
broblasts, cells were seeded at 10,000 per well in 96-well
microplates. At 90% confluency, mitomycin C was added
to triplicate wells at 0, 2, 20, 200, and 2,000 ng/mL. After
48 hours of culture, an MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) in vitro toxicology assay
(Sigma-Aldrich) was carried out in accordance with the in-
structions of the manufacturer and absorbance was mea-
sured at 570 nm on a Multiskan EX plate reader (Thermo
Fisher Scientific). Optical densities of wells treated with mi-
tomycin C were compared with those of untreated wells to
determine cell viability.
To test the viability of microencapsulated MSCs, cap-
sules were dissolved on days 2, 7, 12, 17, and 22 after en-
capsulation by using a solution of 1% EDTA. The
released MSCs were washed with culture medium, incu-
bated for 3 minutes with trypsin-EDTA to create a single
cell suspension, and washed with culture medium, and
the percentage of living cells was determined by using
the Trypan blue exclusion (TBE) assay.
Population doubling time calculations
For determination of population doubling time (PDT),
2 × 105 released MSCs were plated in a T25 tissue cul-
ture flask and cultured in expansion medium. The PDT
was calculated by using the following link: [28]. PDTs of
microencapsulated MSCs were compared with PDTs of
non-encapsulated MSCs from the same horse at the
same passages.
Characterization of mesenchymal stromal cells after
encapsulation
MSCs removed from capsules 2 days after encapsulation
were plated in T75 tissue culture flasks containing ex-
pansion medium until monolayer was 90% confluent. At
that time, cells were collected for flow cytometric ana-
lyses and seeded for differentiation assays as described
previously [15].
Proliferation assays
The effect of mitomycin C on the proliferation of NBL-6
was evaluated by using a bromodeoxyuridine (BrdU)
proliferation assay kit (Abcam, Cambridge, MA, USA).
To this end, NBL-6 were seeded on a 96-well plate at a
density of 5 × 104 cells per well and incubated with mito-
mycin C for 48 hours. Regular medium was used to es-
tablish baseline proliferation. The BrdU proliferation
assay kit was used in accordance with the instructions of
the manufacturer, and the resulting absorbance was read
at 450 nm on a Multiskan EX microplate reader by using
Table 1 Overview of primers used for semi-quantitative reverse transcription-polymerase chain reaction
Gene Abbreviation Forward primer (5′-3′) Reverse primer (5′-3′)
Succinate dehydrogenase complex, subunit A SDHA TCCATCGCATAAGAGCAAAG GGTGGAACTGAACGAACTCC
Plasminogen activator urokinase PLAU TGTGAGATCACTGGCTTTGG TGACATTCCTGGTGGGAAAC
Annexin A2 ANXA2 GCAGTGTCTGTCACCTCCAG CCTCCTTCTTGATGCTCTCC
Cathepsin K CTSK TCCAGAAGGGAAACAAGCAC TCTTATTCCGAGCCATGAGG
CC chemokine-2 CCL2 GGCTCAGCCAGATGCAATTA GCTTTCTTGTCCAGCTGCTT
Metallopeptidase-2 MMP2 GAAGGCTGTGTTCTTTGCAG TCCAGTTAAAGGCAGCATCC
Syndecan-4 SDC4 GCAGCATCTTTGAGAGGACAG GTTTCTTGCCCAGGTCGTAG
Metallopeptidase-1 MMP1 GCCAAATGGACTTCAAGCTG TAGGAAAGCCGAAGGATCTG
Tissue plasminogen activator PLAT AGTTCTTGCTGGCTCCTGTC ATCGGTATGTTCTGCCCAAG
Interleukin-8 IL-8 AGACGCACTCCAAACCTTTC CAGACCTCAGCTCCGTTGAC
Metallopeptidase inhibitor-1 TIMP1 GCTCCCTGGAACAGTCTGAG CGTCCACAAGCAATCAGTGTC
Plasminogen activator inhibitor-1 PAI1 CCCTGGAGAGTGAAGTGGAC CCTGCGATACATGGAGAAGC
Collagen type 1A1 COL1 AAGGACAAGAGGCACGTCTG GCAGGAAAGTCAGCTGGATG
Collagen type 3 COLIII GGGTATAGCTGGTCCTCGTG GCGCCTCTTTCTCCTTTAGC
Fibronectin Fibronectin AGGTCGTTACTGTGGGCAAC TAATGGGAGACGGTGTAGGG
Syndecan-2 SDC2 GACTCAGAAAGGAACGTGGAC ATAACTCCGCCAGCAATGAC
CXC chemokine-10 CxCL10 GACTCTGAGTGGAACTCAAGGAAT GTGGCAATGATCTCAACACG
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USA). Empty wells and wells without BrdU were in-
cluded as controls.
Statistical analyses
Student’s t test for paired data was used to test for statis-
tically significant differences in cell migration (scratch
assays and ECIS), mRNA expression (RT-qPCR), cell via-
bility (TBE and MTT), and BrdU incorporation (enzyme-
linked immunosorbent assay, or ELISA) between untreated
and CM-stimulated NBL-6. Data given are the mean of
three replicates, and the bars show standard deviations
(SDs). To compare data from different individuals, statis-
tical analysis was done by means of the non-parametric
Kruskal-Wallis and Dunn’s mulitiple comparison test
(α = 0.05), and significant differences were considered
at P value of less than 0.01.
Results
Conditioned medium from mesenchymal stromal cells
stimulates migration of dermal fibroblasts in scratch assays
Because dermal fibroblasts are critically involved in
wound healing [29], we decided to study the effects of
MSC-derived CM on the migration of these cells by
using in vitro scratch assays [30]. We found that equine
dermal fibroblast cells (NBL-6) migrated significantly
faster when cultured in CM obtained from equine MSCs
compared with control CM, which was collected from
NBL-6 (Figure 1A).
Given the high incidence of hypergranulation forma-
tion in equine and human wounds [8], it was importantto explore whether this increased rate of wound closure
was due to enhanced migration or increased prolifera-
tion of the fibroblasts or both. Therefore, we repeated
the scratch assays in the presence of mitomycin, an in-
hibitor of proliferation. No differences in migration of
NBL-6 cells cultured in MSC-derived CM in the pres-
ence or absence of mitomycin were found, indicating
that the observed effect in the scratch assays was not
due to an increased proliferation of the cells (Figure 1B).
To ensure that the mitomycin concentration used for
these experiments (that is, 2,000 ng/mL) was effective in
inhibiting proliferation without affecting cell viability, we
performed a BrdU ELISA as well as an MMT assay, re-
spectively (Figure 1C).
To corroborate our findings on the increased migration
of fibroblasts when exposed to MSC-derived CM, ECIS
experiments were used to measure in vitro wound closure
rates [31]. Again, we found that equine dermal fibroblasts
migrated significantly faster when cultured in CM ob-
tained from equine MSCs compared with control CM
with a wound closure of 11.8 ± 0.35 hours versus 15.3 ±
0.96 hours, respectively (Figure 2A, B). Because the ECIS
system creates only a very small wound (350 μm) that nor-
mally heals in 12 to 18 hours, cell migration rather than
proliferation is the major contributor to closure under
these conditions (Figure 2C). Interestingly, the ending
impedance value shown in Figure 2A of the MSC CM-
treated fibroblasts was higher than that of the control, in-
dicating that the addition of the MSC CM may increase
either cell-cell or cell-matrix contacts on the healed fibro-
blast monolayer leading to a higher final impedance.
Figure 1 Mesenchymal stromal cell (MSC) conditioned medium (CM) promotes migration of dermal fibroblasts in scratch assays (n = 3). (A)
Representative phase-contrast images of wounded NBL-6 cells cultured with MSC-derived CM (lower panels) as compared with control CM (upper
panels) over a 48-hour period, and migration distances of NBL-6 cells are expressed as micrometer per hour in 48 hours. **P <0.01. (B) Migration
of NBL-6 cells cultured with MSC-derived CM as compared with CM from mitomycin C-treated MSCs (2,000 ng/mL). (C) Viability (dashed line)
and proliferation (solid line) of NBL-6 cells cultured in the presence of various concentrations of mitomycin C. NBL-6, horse dermal fibroblast cell;
OD, optical density.
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induces alterations in the expression of genes involved in
wound healing
Semi-quantitative RT-PCR analyses were performed to
investigate the relative mRNA expression levels of se-
lected inflammatory cytokines, remodeling enzymes,
extracellular matrix components, and adhesion mole-
cules, all associated with wound repair, in NBL-6 cul-
tured with MSC-derived CM as opposed to control CM.
Figure 3A shows the experimental set-up for these stud-
ies, and it was observed that culturing dermal fibroblastsin the CM of MSCs differentially regulated mRNA ex-
pression of several genes involved in wound healing
when compared with gene expression in dermal fibro-
blasts cultured in control CM (Figure 3B). A signifi-
cant upregulation of the pro-inflammatory mediator
interleukin-8 (IL-8) (P <0.05) and a significant down-
regulation of the chemokine C-X-C motif chemokine
10 (CxCL10) (P <0.01) were observed in dermal fibro-
blasts cultured in the presence of MSC-derived CM
(Figure 3B). Gene expression levels of extracellular
matrix components and adhesion molecules were not
Figure 2 Mesenchymal stromal cell (MSC) conditioned medium (CM) promotes wound closure using Electric Cell-substrate Impedance Sensing
(n = 3). Wound-healing rates of NBL-6 cells cultured with MSC-derived CM or control CM, as determined by electrical impedance in ohms detected
from 0 to 24 hours after wounding (A) and total wound closure time expressed in hours (B). **P <0.01. (C) Phase-contrast images of wounded NBL-6
cells cultured with MSC-derived CM (upper panels) as compared with control CM (lower panels) over a 24-hour period. Scale bars = 100 μm. NBL-6,
horse dermal fibroblast cell.
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3 (COLIII), which was significantly lower in dermal fi-
broblasts cultured in the presence of MSC-derived CM
compared with control CM (P <0.05) (Figure 3B). Fi-
nally, the expression of a variety of remodeling enzymes
was upregulated when dermal fibroblasts were cultured
in CM, with matrix metalloprotease protein 1 (MMP1)
showing a significantly higher expression in dermal fi-
broblasts cultured in the presence of MSC-derived CM
compared with control CM (P <0.01) (Figure 3B).
Conditioned medium of mesenchymal stromal cells
stimulated with TNFα, IFNγ, or COCl2 further alters gene
expression in dermal fibroblast cells but does not result
in an increased migration capacity
Since it has been reported previously that pre-
stimulation of human MSCs increased their wound-
healing properties [32-35], we stimulated our equineMSCs with TNFα, IFNγ, and COCl2 to evaluate the ef-
fects on (i) expression of wound healing-related genes in
NBL-6 cells and (ii) in vitro scratch assays. It was ob-
served that stimulation of MSCs with TNFα led to a sig-
nificant increase in MMP1 (P <0.01) and IL-8 (P <0.05)
mRNA expression in NBL-6 cells but that stimulation
with IFNγ led to a significant increase in CxCL10 ex-
pression (P <0.05) compared with culturing NBL-6 cells
with CM of non-stimulated MSCs (Figure 3C). In con-
trast, none of the stimulating agents influenced the ex-
pression of COLIII, and stimulation of MSCs with
CoCl2 had no effect on the expression of any of the
evaluated genes (Figure 3C). During evaluation of these
pre-stimulation treatments in scratch assays, no differ-
ences in migration rates were observed between fibro-
blasts exposed to the stimulated MSC-derived CM versus
the non-stimulated MSC-derived CM (Additional file 1:
Figure S1A, B).
Figure 3 Mesenchymal stromal cell (MSC) conditioned medium (CM) alters gene expression levels in dermal fibroblasts (n = 3). (A) Schematic
illustration of NBL-6 treatments for RNA isolation. Fold change of mRNA levels, as detected by quantitative reverse transcription-polymerase chain
reaction, in (B) NBL-6 cells cultured with MSC-derived CM as compared with control CM or (C) NBL-6 cells cultured with CM from preconditioned
MSCs as compared with CM from non-preconditioned MSCs. Left panel shows genes involved in reduction of hypergranulation or enhancement
of wound healing or both, and right panel shows genes that stimulate hypergranulation or delay wound healing or both. *P <0.05; **P <0.01.
ANXA2, annexin A2; CCL2, CC chemokine 2; CoCl2, cobalt chloride; COLI, collagen type 1A1; COLIII, collagen type 3; CTSK, cathepsin K; CxCL10,
CXC chemokine 10; IFNγ, interferon-gamma; IL-8, interleukin-8; MMP1, metallopeptidase 1; MMP2, metallopeptidase 2; NBL-6, horse dermal fibroblast
cell; PAI1, plasminogen activator inhibitor-1; PLAT, tissue plasminogen activator; PLAU, plasminogen activator urokinase; SDC2, syndecan 2; SDC4,
syndecan 4; TIMP1, metallopeptidase inhibitor 1; TNFα, tumor necrosis factor-alpha.
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medium on the expression of wound healing-related
genes are donor-dependent in our study
When we studied the changes in gene expression in
more detail, it became clear that potential significant dif-
ferences in gene expression levels could be masked be-
cause of the rather large SDs we observed for several
tested genes. Since we used the CM of MSCs from three
different individual horses for our experiments, wereasoned that these large SDs could be caused by natural
inter-horse variations. Therefore, we decided to present
the results of the gene expression alterations per individ-
ual donor horse instead of using the average (Additional
file 2: Figure S2A). By presenting the data this way, we
made several observations. Firstly, when the non-
parametric Kruskal-Wallis test was used to compare the
gene expression data between horses, statistically signifi-
cant differences between individuals became apparent in
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At a P value of less than 0.01, there were statistically sig-
nificant differences for two hypergranulation reducers
or wound-healing enhancers or both, namely cathepsin
K (CTSK) and matrix metalloproteinase-2 (MMP2)
(Table 2A). Likewise, statistically significant differences
(P <0.01) between horses were found for four hypergra-
nulation enhancers or wound-healing reducers or both,
namely plasminogen activator inhibitor 1 (PAI1), colla-
genase type III (COLIII), fibronectin, and SDC2
(Table 2B). Secondly, with Dunn’s post hoc test, it was
observed that culturing NBL-6 cells in the MSC-
derived CM of horse B resulted in a significant mean
rank difference of at least 6 for the genes CTSK,
MMP2, PAI1, and COLIII when compared with NBL-6
cells that were cultured in the CM of either horse A- or
horse C-derived MSCs (Additional file 2: Figure S2B).
Overall, the increased expression levels of CTSK and
MMP2, genes advantageous for wound healing, with a
simultaneously decreased expression level of PAI1, a
gene disadvantageous for wound healing, would make
horse B a better donor for providing MSCs with the
capacity to promote wound healing than either horse A
or C. Using scratch assays to compare the effects of
horse B MSC-derived MSCs on migration of fibroblasts
with the other two horse MSC samples revealed no statis-









A. Hypergranulation reducers or wound-healing enhancers or both
PLAU - - -
ANXA2 - Yesa -
CTSK - Yesb -
CCL2 - Yesa -
MMP2 - Yesb -
SDC4 - - -
MMP1 - - -
PLAT - - -
IL-8 - - Yesa
B. Hypergranulation enhancers or wound-healing reducers or both
TIMP1 - Yesa -
PAI1 - Yesb -
COLI - - -
COLIII - Yesb -
Fibronectin Yes** - -
SDC2 - - Yesb
aP <0.05; bP <0.01.could equally increase NBL-6 migration (P <0.01,
Additional file 2: Figure S2C). Taken together, these
data indicate that the expression level pattern in CM-
treated dermal fibroblast cells is donor horse MSC-
specific in our study.
Encapsulated mesenchymal stromal cells retain stem cell
characteristics and remain viable during long-term
encapsulation
After clearly demonstrating that the CM of equine
MSCs promotes wound healing, we were interested in
exploring the potential of microencapsulating MSCs as a
way to deliver the critical components of CM to
wounded cells in vitro in a controlled manner. In a first
set of experiments, we encapsulated equine MSCs and
2 days later removed these MSCs from their capsules to
evaluate whether they retained their stem cell character-
istics. Overall, the immunophenotypical profile, as de-
tected by flow cytometric analysis using a commonly
used set of cell surface markers [36], did not differ be-
tween MSCs removed from capsules and MSCs that
were never encapsulated (Figure 4A). There was a sig-
nificant difference (P <0.05) in the expression of MHC I,
but this marker is known to be highly variably expressed
by MSCs [37]. In addition, MSCs removed from capsules
retained the capacity to differentiate into osteocyte,
chondrocyte, and adipocyte lineages (Figure 4B). More-
over, the PDT of MSCs removed from capsules was vir-
tually identical to that of MSCs from the same source,
but never encapsulated, from passage 13 to 17 (end of
experiment) (Figure 4C).
In a second set of experiments, we cultured MSCs in
capsules for over 3 weeks in order to test the potential
of long-term encapsulation. MSCs encapsulated for
2 days were used as the short-term encapsulation control
time point (day 2) and compared with MSCs encapsulated
for successive 5-day intervals (days 7, 12, 17, and 22). At
all of these different time points, equine MSCs were re-
moved from equal numbers of capsules and subsequently
plated in culture wells (Figure 5A). Before plating, viability
was determined by using TBE and the number of live cells
was determined. Over the course of the experiment, the
viability of long-term encapsulated cells decreased slightly
compared with short-term encapsulation but did not fall
below 80% and this slight decrease was not statistically
significant (Figure 5B). In addition, the number of viable
cells present in the capsules for 7 days was significantly in-
creased compared with 2-day encapsulation, indicating
that equine MSCs did divide in the capsules, but remained
constant thereafter (Figure 5C). After plating and upon
confluency of the cells, PDTs were calculated. Cells encap-
sulated for 7 days showed a PDT similar to that of the
short-term, 2-day, encapsulated MSCs. In contrast, cells
encapsulated for more than 7 days showed a significantly
Figure 4 Mesenchymal stromal cells (MSCs) retain stem cell characteristics after microencapsulation (n = 3). (A) Expression of surface markers,
as detected by flow cytometry, on MSCs removed from capsules after 2 days post-encapsulation as compared with control MSCs that were
never encapsulated. Percentage of total cells positive is shown on the left, and representative histograms are shown on the right. *P <0.05.
(B) Representative images of MSCs stained with Alizarin Red, Alcian Blue, and Oil Red O to detect osteocyte, chondrocyte, and adipocyte
differentiation, respectively. Left column: undifferentiated MSCs cultured in expansion medium; center column: control MSCs that were never
encapsulated cultured in MSC differentiation media; and right column: MSCs removed from capsules after 2 days post-encapsulation cultured
in MSC differentiation media. Scale bars = 10 μm. (C) Population doubling times of MSCs removed from capsules after 2 days post-encapsulation as
compared with control MSCs that were never encapsulated. MHC, major histocompatibility complex.
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longer to form a confluent monolayer (Figure 5D). For
the duration of this set of experiments, pictures from
confluent monolayers were taken daily to confirm that
the stem cell morphology was maintained, indicating
that the change in PDT was not due to differentiation
of the MSCs which could result in an altered growth
pattern (Figure 5E).Encapsulated mesenchymal stromal cell-derived
conditioned medium stimulates migration of dermal
fibroblasts and induces alterations in the expression of
genes involved in wound healing
After showing that microencapsulated MSCs remain vi-
able and retain general stem cell characteristics, we eval-
uated the CM from encapsulated MSCs in order to
determine potential positive effects on dermal fibroblast
Figure 5 Mesenchymal stromal cells (MSCs) remain viable after long-term microencapsulation (n = 3). (A) Representative images of MSCs encapsulated
(left), immediately after removal of capsules (center), and after several days of culture (right). (B) Viability, as determined by Trypan blue exclusion, of
MSCs removed from capsules at 5-day intervals starting at 2 days after encapsulation. (C) Numbers of viable cells removed from equal numbers of
capsules at 5-day intervals starting at 2 days after encapsulation. **P <0.01. (D) Population doubling times of MSCs removed from capsules at
5-day intervals starting at 2 days post-encapsulation. **P <0.01. (E) Representative phase-contrast images of cultured MSCs removed from
capsules 22 days post-encapsulation as compared with control MSCs that were never encapsulated. Scale bars = 50 μm.
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healing. To this end, we repeated the scratch assays and
gene expression analyses, as previously described, by
using CM from non-encapsulated MSCs (control) and
from MSCs that were encapsulated and cultured for
2 days.
Using scratch assays, we found that NBL-6 cells had
an equally fast migration when cultured in CM obtained
from equine MSCs compared with CM obtained from
encapsulated equine MSCs (Figure 6A). CM that was
collected from 2-day cultured empty capsules was also
included as a control and showed a significantly slower
migration compared with either MSC-derived CM (data
not shown). Next, semi-quantitative RT-PCR analyses
were performed on NBL-6 cells cultured in CM obtained
from non-encapsulated MSCs (control, set as 1) and
compared with gene expression in NBL-6 exposed to
CM obtained from encapsulated MSCs. Specifically, therelative mRNA expression levels of a selected set of
genes (that is, IL-8, MMP1, ColIII, and CxCL10) in-
volved in wound healing were determined. A significant
upregulation of IL-8 and MMP1 gene expression was
observed in NBL-6 cells cultured in CM obtained from
encapsulated equine MSCs as compared with NBL-6
cells which were cultured in CM of non-encapsulated
MSCs (Figure 6B). In contrast, the gene expression levels
of COLIII and CxCL10 were indistinguishable between
NBL-6 cells cultured in CM from either encapsulated
MSCs or non-encapsulated MSCs (Figure 6B).
Discussion
The present study is the first to evaluate the effects of
CM from equine MSCs on wound-healing properties of
equine dermal fibroblasts and to explore the potential of
encapsulated equine MSCs to deliver these critical com-
ponents to equine target cells. Our salient findings were
Figure 6 Conditioned medium (CM) from microencapsulated mesenchymal stromal cells (MSCs) promotes NBL-6 migration and alters gene
expression (n = 3). (A) Migration distances of NBL-6 cells cultured in CM from encapsulated MSCs as compared with MSC CM in in vitro scratch
assays. Data are expressed as micrometer per hour in 48 hours. (B) Fold change of mRNA, as detected by quantitative reverse transcription-polymerase
chain reaction, in NBL-6 cells cultured with encapsulated MSC CM as compared with control MSC CM. Left panel shows genes involved in reduction of
hypergranulation or enhancement of wound healing or both, and right panel shows genes that stimulate hypergranulation or delay wound healing or
both. *P <0.05. COLIII, collagen type 3; CxCL10, CXC chemokine 10; IL, interleukin; MMP1, metallopeptidase 1; NBL-6, horse dermal fibroblast cell.
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equine dermal fibroblasts in vitro and increases the ex-
pression levels of genes that positively contribute to
wound healing. Importantly, similar results were ob-
tained by using CM from MSCs that were encapsulated
in core-shell hydrogel microcapsules, indicating the po-
tential of microencapsulated MSCs to deliver the bio-
active factors present in CM.
During our studies on the expression levels of genes
involved in wound healing when equine fibroblasts were
exposed to MSC-derived CM, two interesting observa-
tions were made. First, we found a highly significant,
four-fold, increase in the mRNA expression of the
MMP1. MMP1, also designated interstitial collagenase
or fibroblast collagenase, is a critical remodeling enzyme
required for re-epithelialization during wound healing[38,39]. In vitro studies have shown that CM from
amnion-derived human MSCs alters the expression of
MMP1 in human dermal fibroblasts [35], which is simi-
lar to our present findings with CM from peripheral
blood-derived equine MSCs and equine dermal fibro-
blasts. Interestingly, the CM collected from MSCs that
were microencapsulated even further altered the expres-
sion of MMP1 as evidenced by a significantly higher
MMP1 expression in dermal fibroblasts when exposed
to the CM from microencapsulated MSCs compared
with CM from non-encapsulated MSCs (Figure 6B). A
similar observation was made for IL-8 expression in der-
mal fibroblasts (Figure 6B), another critical component
in cutaneous wound healing known to stimulate migra-
tion and proliferation of keratinocytes [40]. Although it
is speculative at this point, we hypothesize that the close
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sule microenvironment or both changes the secretion
pattern of MSCs or, alternatively, that the MSC secre-
tome is influenced by adherent (non-encapsulated) ver-
sus non-adherent (encapsulated) culture conditions. An
increased expression level of MMP1 and IL-8 in dermal
fibroblasts was also observed when equine MSCs were
preconditioned by using TNFα. TNFα has been de-
scribed to stimulate human MSC to secrete elevated
levels of IL6 and IL8, resulting in accelerated wound
healing [29]. Our study shows that IL8 is also upregu-
lated in equine target cells exposed to CM from TNFα
treated equine MSC. For the two other agents that we
used to precondition equine MSCs in our present study,
however, we did not observe an upregulation of IL-8 or
MMP1 in dermal fibroblasts when exposed to CM from
these stimulated MSCs. The first agent, CoCl2, is a
chemical known to mimic hypoxia, and our results in
our equine model reflect results from a previous study
in which no significant alterations were found in the ex-
pression levels of MMP1 in human dermal fibroblasts
incubated with CM from hypoxic human MSCs when
compared with CM from normoxic human MSCs [35].
In addition, no significant alterations were found in any
of the other genes that were tested (that is, IL-8, COLIII,
and CxCL10) when equine fibroblasts were exposed to
the CM of CoCl2-treated equine MSCs. The second
agent we used to stimulate equine MSCs was IFNγ, a
cytokine known to stimulate MSCs to increase wound
healing in aged mice [33] but for which the specific ef-
fects on the expression of wound-related factors in tar-
get cells, like dermal fibroblasts, have not previously
been investigated. We found in our present study that
equine dermal fibroblasts showed a significant increase
in CxCL10 expression when incubated with CM of
IFNγ-preconditioned MSCs. CxCL10 is a chemokine
known to delay wound healing and to disorganize neo-
vascularization [41], and although more in-depth studies
are needed, we would like to argue that pretreating
MSCs with IFNγ might not be beneficial as a regenera-
tive treatment to promote cutaneous wound healing.
Secondly, we observed that the expression level pat-
tern in CM-treated dermal fibroblast cells was donor
horse MSC-specific. Although our current study is too
limited in experimental numbers and is lacking repeated
isolations from the same donor horse to draw definite
conclusions about donor dependency, our data are the
first to indicate a donor-specific effect of MSC-derived
CM on skin target cells specifically. This study and other
studies describing donor variation in the cytokine ex-
pression level and in vitro bone tissue repair potency of
human MSCs [42,43] collectively suggest that screening
of candidate MSC donors is critical in order to take full
advantage of the therapeutic effects of MSCs oncutaneous wound healing. Moreover, it is important to
take into account the specific purpose of the regenerative
therapy, as the CM of one donor MSC culture might prove
more beneficial than the CM of another MSC culture, de-
pending on the desired therapeutic effect.
Despite the exciting potential of the MSC-derived CM
as an effective cell-free therapeutic treatment in regen-
erative medicine, a major impediment to its use is the
fact that these MSC formulations are not fully optimized
in terms of delivery methods. The ability to control se-
cretion of MSC-derived bioactive factors is critical given
the limitations of pharmacokinetics and stability of pro-
teins in vivo. To begin exploring the potential of such
delivery methods, we microencapsulated our equine
MSCs by using core-shell hydrogel microcapsules. Con-
ventional alginate microcapsules have been used suc-
cessfully to encapsulate human MSCs [44-47]. However,
our study demonstrated that this approach is feasible for
equine MSCs by using core-shell capsules which were
designed to provide a more relevant extracellular envir-
onment and to better protect the encapsulated cells [24].
Indeed, we showed that equine MSCs survive and divide
within these microcapsules and retain their stem cell
characteristics. Importantly, we found that CM collected
from these encapsulated equine MSCs equally promotes
dermal fibroblast migration when compared with the
CM from non-encapsulated MSCs, suggesting that en-
capsulating of MSCs may be an ideal strategy to control
the delivery of secreted products to equine wounds in vivo.
Based on data we have collected thus far, future experi-
ments are planned in which we will evaluate the healing-
promoting effects of equine MSCs, non-encapsulated as
well as microencapsulated, in an in vivo horse model,
such as the horse model established by the group of
Theoret et al. in which skin wounds are experimentally
induced to heal both normally as well as with the for-
mation of exuberant granulation tissue [48].
Conclusions
MSCs have been reported to provide paracrine signals that
promote wound healing, but (i) how they exert their ef-
fects on target cells is unclear and (ii) a suitable delivery
system to supply these MSC-derived secreted factors in a
controlled and safe way is unavailable. The present study
was designed to provide answers to these questions by
using the horse as a translational model. Our results sug-
gest that CM of MSCs might be a promising new therapy
for impaired cutaneous wounds and that microencapsula-
tion may be a suitable way to effectively deliver CM to
wounded cells in vivo. Moreover, our data showed that the
effects of MSC-derived CM appear to be donor-specific,
suggesting that a proper screening of candidate MSC do-
nors is critical in order to take full advantage of the thera-
peutic effects of MSCs on cutaneous wound healing.
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Additional file 1: Figure S1. Conditioned medium (CM) from
preconditioned mesenchymal stromal cells (MSCs) does not affect
migration of dermal fibroblasts (n = 3). (A) Representative phase-
contrast images of wounded NBL-6 cells cultured with CM of MSCs
stimulated with tumor necrosis factor-alpha (TNFα), interferon-gamma
(IFNγ), or cobalt chloride (CoCl2) as compared with control MSC CM at
0, 24, and 48 hours. (B) Migration distances of NBL-6 cells cultured with
CM of MSCs stimulated with TNFα, IFNγ, or CoCl2 as compared with
control MSC CM. Data are expressed as micrometers per hour in
48 hours. NBL-6, horse dermal fibroblast cell.
Additional file 2: Figure S2. Mesenchymal stromal cell (MSC)
conditioned medium (CM) alters horse dermal fibroblast cell (NBL-6)
gene expression in a donor-specific manner (n = 3). (A) Fold change of
mRNA, as detected by quantitative reverse transcription-polymerase chain
reaction (qRT-PCR), in NBL-6 cells cultured with MSC CM from three
different donor horses as compared with control NBL-6 CM. Left panel
shows genes involved in reduction of hypergranulation or enhancement
of wound healing or both, and right panel shows genes that stimulate
hypergranulation or delay wound healing or both. (B) Expression levels
of cathepsin K (CTSK) and metallopeptidase 2 (MMP2) (genes involved in
reduction of hypergranulation or enhancement of wound healing or
both) and plasminogen activator inhibitor-1 (PAI1) and collagen type 3
(ColIII) (genes that stimulate hypergranulation or delay wound healing or
both) with a significant mean rank difference of at least 6 upon incubation
with horse B MSC-derived CM. (C) Migration distances of NBL-6 cells
cultured with CM of MSCs from three different donor horses as compared
with control CM. Data are expressed as micrometers per hour in 48 hours.
**P <0.01.Abbreviations
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